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Abstract 
Background:  To compare vitamin D levels in 
patients of dengue hemorrhagic  fever  with dengue 
fever 
Methods: A total of 50 patients with diagnosed 
dengue fever, who fulfilled the inclusion criteria 
were enrolled in the study. Patients were divided 
into two groups having 25 participants each; one 
group had Dengue fever (DF) while the other was 
suffering from dengue hemorrhagic fever (DHF).  
Vitamin D was estimated by chemiluminescence 
method.  Pearson’s Chi square was applied to 
compare the proportion of patients in each study 
group. Relative Risk was measured along with 95% 
confidence interval. Significant p- value was < 0.05. 
Results: Mean age of patients was 37.79 ± 15.2 years 
(range: 16-90 years). There were 74% males and  26% 
females. Mean vitamin D levels in dengue fever 
patients were higher (21.5 ± 13.6 ng/ml) as compared 
to Dengue hemorrhagic fever (12.4 ± 5.6 ng/ml). 
Difference was statistically significant (p=0.003).  
Conclusions: Vitamin D may have a role in 
management of dengue fever. Low levels of vitamin 
D might be associated with dengue hemorrhagic 
fever. 
Key Words: Vitamin D, Dengue fever, Dengue 
hemorrhagic fever   
 
Introduction 
Dengue is a viral infection in humans which spreads 
by mosquitoes around the world. It is one of the 
serious global health challenges that have emerged 
now a days. Dengue is a flavivirus. It has four 
serotypes (DV-1, DV-2, DV-3, and DV-4). People 
suffering from Dengue infection may be asymptomatic 
or having undifferentiated fevers. Other mild form of 
the disease is dengue fever (DF). Small proportions of 
patients suffer from dengue hemorrhagic fever (DHF) 
and dengue shock syndrome (DSS) that may be fatal. 
Few studies have shown altered plasma concentrations 
of vitamin D are associated with the pathogenesis of 
dengue infection. DENV infection has been reported in 
over 100 countries and approximately 2.5 billion 
people live in endemic regions.  The current estimate 
of the number of annual dengue cases is 100 million 
for DF and 250,000 for DHF, with a total of 25,000 
deaths per year.1 Dengue is a febrile illness and is 
responsible for causing morbidity throughout the 
tropical and subtropical regions of the world. There 
are more than 70 members of Flaviviridae,  in which 
DENV is a single positive-stranded RNA virus 
transmitted by the mosquitoes Aedes 
aegypti and Aedes albopictus.1,2 There are four 
different serotypes of DENV (DV-1, DV-2, DV-3, and 
DV-4) that cause dengue fever.3  
The clinical manifestations of DENV infection may 
vary from asymptomatic infection, undifferentiated 
fever, or it can present with DF,DHF, and DSS which 
are the three clinical manifestations in humans. DF is 
the least severe, non fatal form which presents with flu 
like symptoms. DHF includes hemorrhagic 
manifestations such as spontaneous bleeding, 
decreased platelet count, and evidence of increased 
vascular permeability noted as increased 
hemoconcentration or pleural effusion or ascites. DHF 
may progress to hypovolemic shock known as DSS 
which is characterized by a rapid, weak pulse, narrow 
pulse pressure (≤20 mm Hg) or hypotension with cold, 
clammy skin in the early stage of shock.  4 Both DHF 
and DSS can be life-threatening and cause mortality in 
many cases. It has been found in a study that dengue 
virus titers are significantly higher (upto 1000 fold) in 
patients with DHF  and DSS as compared to those 
having DF in the initial phase of infection.5 Severity of 
Dengue virus infection is more common in children 
than adults.6 
The outcome of DENV infection is determined by 
multiple factors including viral virulence, host genetics 
and host immune responses7. The pathophysiology of 
DENV in the body and the host's immune response are 
not completely understood. It is believed that virus 
Journal of Rawalpindi Medical College (JRMC); 2018;22(2): 92-95 
 93 
binds itself to host cells and this binding is mediated 
by major viral envelope (E) glycoprotein present in the 
virus8. This is followed by entering of virus in the cell 
and its replication. It is believed that monocytes play 
an important role and they produce interferon-α (IFN-
α) and IFN-β.9, 10 E precursor membrane protein (pre-
M), and nonstructural protein 1 (NS1) are the major 
proteins on DENV that are targeted by antibodies as 
part of the host immune response. These infected cells 
are attacked by CD4+ and CD8+ T lymphocytes 
resulting in release of lymphotoxins, anti 
inflammatory cytokine (IL-10), tumor necrosis factor-α 
(TNF-α) and interferon-γ, all contributing to the 
pathogenesis of disease. 11-13 There are various 
immunomodulators, the presence or absence of which 
influence the outcome of the disease by activating T 
cells, antibodies and cytokines. 14 
Primary infection induces lifelong immunity in the 
individual to that particular serotype but not to 
secondary infection by a different serotype. If 
secondary infection occurs, disease severity may be 
exacerbated by CD4+ and CD8+ T lymphocytes and 
preexisting antibodies15. Various studies have shown a 
relationship between secondary DENV infection and 
its hemorrhagic manifestations.  
Host nutritional status is a strong predictor of 
immunity.16 Host nutritional status or micronutrient 
supplementation as adjuvant therapy could lower the 
probability of progressing from DENV infection to 
overt/severe forms of disease or reduce disease 
severity in patients.17 Vitamin D has an antiviral 
activity and regulates inflammatory response. By 
binding to VDR (Vitamin D receptor), it influences 
gene expression by translocating to the nucleus. As a 
result of which phagocytic activity of macrophages is 
increased which induce antimicrobial peptide gene 
expression contributing to innate immune responses.18 
 Vitamin D also enhances Th2 cytokine and IL-10 
responses, whereas it inhibits cytotoxic T cell and T-
helper 1 (Th1) cell responses. 19 
A study from Vietnam has shown the association of 
vitamin D receptor gene polymorphisms with 
susceptibility to DHF.20 Thus Vitamin D could 
modulate pathways leading to dengue hemorrhagic 
fever/dengue shock syndrome. 
 
Patients and Methods 
 
A total of 50 patients with diagnosed dengue fever, 
who fulfilled the inclusion criteria were enrolled in  
the study from September,2016 to November,2016 
from Benazir Bhutto Hospital after getting ethical 
review board approval. Patients were divided into two 
groups having 25 participants each; one group had 
Dengue fever (DF) while the other was suffering from 
dengue hemorrhagic fever (DHF).  Data was recorded 
in self-structured questionnaire.Data was analyzed 
using SPSS Version 21. Numerical data like age, 
Vitamin D levels was presented as mean ± standard 
deviation. Categorical data was presented as 
frequencies.  Pearson’s Chi square was applied to 
compare the proportion of patients in each study 
group. Relative Risk was measured along with 95% 
confidence interval. Significant value was < 0.05. 
 
Results 
During the study period of three months, total 50 
patients were included in the study after taking 
informed consent. Mean age of patients was 37.79 ± 
15.2 years (range: 16-90 years). There were 37 (74%) 
males while 13 (26%) were females. Out of total 50 
patients, 25 patients were diagnosed having Dengue 
fever and 25 having dengue hemorrhagic fever. (Table 
1). Comparison of clinical features as well as Vitamin 
D levels in both groups was done. Mean vitamin D 
levels in dengue fever patients were higher (21.5 ± 13.6 
ng/ml) as compared to dengue hemorrhagic fever 
(12.4 ± 5.6 ng/ml). Independent sample t test showed 
that the difference is statistically significant (p=0.003) 
(Table 2).  
 
Table-I: Age and Gender of the patients (n=50) 
Variable Dengue 
fever(n=25) 
Dengue 
Hemorrhagic 
fever(n=25) 
p- value 
Age(mean ± 
SD) 
39.1± 17.6 34.04 ± 11.89 0.05* 
Gender n(%) 
Male 15(60) 22(88) 0.05# 
Female 10(40) 3(12) 
* Independent sample t test;# Chi square test 
Table 2: Vitamin D levels of the patients (n=50) 
Variable Dengue 
fever(n=25) 
Dengue 
Hemorrhagic 
fever(n=25) 
p- 
value 
Vitamin D 
Levels 
(ng/ml) 
21.5± 13.6 12.4 ± 5.6 0.003* 
* Independent sample t test;# Chi square test  
 
Discussion 
In present study, Vitamin D levels were higher in 
patients with DF (21.5 ± 13.6) as compared to the 
patients with DHF (12.4 ± 5.6) with significant P 
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value= 0.003.  Vitamin D3 is a potentially useful 
antiviral compound and is known to affect the disease 
process of dengue by altering immune responses.21 
There is an increased susceptibility of viral infections 
and autoimmune diseases with vitamin D deficiency.22 
Vitamin D causes monocyte differentiation and T-cell 
activation by binding to vitamin D receptors and 
activating vitamin D-responsive genes in the body. 
Vitamin D inhibits cytotoxic T cell responses as well as 
T-helper 1 (Th1) cell. It also enhances responses of IL-
10 and Th2 cytokine. 23 
In many larger studies, risk of several other infections 
is lowered by Vitamin D supplementation. In a study, 
two cases of immune thrombocytopenia were reported 
to be successfully treated by high-dose vitamin D 
supplementation and hydroxychloroquine. It was 
suggested that vitamin D3 down regulated CD4+ T 
cells and up regulated T-regulatory cells, which 
eventually restored platelet levels.24 White blood cells 
also become activated by binding of vitamin D to VDR 
(vitamin D receptors) present on their surface. Hence 
deficiency of vitamin D can lead to leucopenia. This 
could be another explanation that decreased levels of 
vitamin D increases the clinical risk and severity of 
DENV infection. 
A recent study conducted by Ahmed S, Finkelstein JL, 
et al in 2014 emphasized the importance of 
micronutrients including vitamins D and E in dengue 
virus infection 17. The relationship between vitamin D 
and DENV infection in patients with dengue have 
been investigated in multiple studies.. In another 
study Guardo PH, Medina F, et al found that vitamin 
D3 significantly reduced the levels of pro-
inflammatory cytokines (TNF-α, IL-6, IL-12p70 and IL-
1β) produced by infected U937 cells and, exposure to 
Vitamin D3 significantly reduced the number of 
infected cells, particularly in monocytic cells, and 
lowered the production of pro-inflammatory 
cytokines.25 This study showed that inhibition of 
DENV infection is directly related to the dosage of 
vitamin D3. 
Another study conducted at Benazir Bhutto Hospital, 
Rawalpindi showed significant therapeutic role of 
Vitamin D in progression of DF to DHF. Of 124 
patients selected, those who received Vitamin D 
progressed less to DHF (1.6%) as compared to those 
who did not receive it (27%).26 
Alagarasu showed that vitamin D might induce its 
effects on Fcγ-receptor expression. Fcy receptors are 
responsible for entry of virus in human cells. As a 
result of which patients who become secondarily 
infected with dengue fever have possibly higher viral 
load and have higher chances of development of DHF 
 and DSS. Hence Vitamin D might influence viral entry 
into cell. 27   
There are a few smaller studies that show relationship 
between DENV infection and vitamin D receptor 
polymorphisms. Due to polymerization, there is defect 
in signaling of vitamin D receptor which results in 
inadequate response leading to decreased Interleukin -
10 levels and raised Tumor Necrotic Factor-α levels, 
eventually causing leading to DHF. This is in contrast 
to a large study conducted in Vietnam known as 
Genome-wide association study (GWAS) which failed 
to find association between vitamin D receptor genes 
and DENV infection.28 However GWAS study was 
about DSS and was conducted in children. 
It is believed that reduction in severity as well as 
progression from dengue fever to more severe forms 
such as DHF  and DSS is influenced by micronutrient 
supplementation or host nutritional status. Because of 
insufficient data, there are very few studies that make 
any specific recommendations about Vitamin D3 
levels, micronutrients including Vitamin D3 and 
DENV infection. Additionally, there is limited 
information about relationship between beneficial 
effect of nutritional supplements including vitamin D 
and it’s the optimal timing during the course of the 
illness.  
 
Conclusion 
Vitamin D may have a role in management of dengue 
fever. Low concentrations of vitamin D might be 
associated with dengue hemorrhagic fever.  
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